---
document_datetime: 2023-09-21 19:16:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/plavix-epar-procedural-steps-taken-authorisation_en.pdf
document_name: plavix-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3837246
conversion_datetime: 2025-12-24 20:08:13.053329
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Sanofi Pharma Bristol-Myers Squibb SNC, France submitted on 9 April 1997 to the European Agency for the Evaluation of Medicinal Products (EMEA) an application for the marketing authorisation of the medicinal product Plavix falling within the scope of Part B of the Annex of the Council Regulation (EEC) 2309/93, of 22 July 1993.

The Rapporteur and Co-rapporteur appointed by the CPMP were as follows:

Rapporteur: Prof. M. Forte

## Licensing status:

Plavix has been licensed in the USA since 17 November 1997.

## 2. Steps taken for the assessment of the product

- The Rapporteur's assessment report was circulated to all CPMP Members on 28 July 1997. The Co-Rapporteur's assessment report was circulated to all CPMP Members on 25 July 1997.
- The CPMP Consolidated list of questions was adopted on 24 September 1997.
- The responses to the consolidated list of questions were received on 8 December 1997.
- The Joint Rapporteur/Co-Rapporteur assessment report on the responses to the consolidated list of questions was circulated on 21 January 1998.
- The  company  submitted  written  responses  on  the  outstanding  chemical  and  pharmaceutical issues on 20 February 1998.
- During  its  meeting  on  24  February  1998,  the  CPMP  agreed  on  a  list  of  outstanding  clinical issues to be addressed by the company in an oral explanation.
- A hearing was held on 24 February 1998, to address the outstanding clinical issues.
- The CPMP, during its meeting on 23-25 February 1998, considered the responses provided by the company, and discussed the recommendations presented by the Rapporteur.
- The CPMP, during its meeting on 23-25 February 1998, considered the responses provided by the  company  to  some  of  the  clinical  issues  not  to  be  satisfactory.  Therefore,  the  CPMP requested additional written information to be submitted.
- On the basis of the responses provided by the company, the CPMP discussed and amended the Summary  of  Product  Characteristics  following  additional  oral  explanations  provided  by  the company on 24 March 1998.
- A letter of undertaking on the follow-up measures as requested by the CPMP, was signed by the applicant on 25 March 1998.
- During the meeting on 25 March 1998, the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation .
- On 15 July 1998, the European Commission issued a Marketing Authorisation for Plavix.

Co-Rapporteur: Pharm. G. De Greef